ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PAR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Paradigm Biopharmaceuticals alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Paradigm Biopharmaceuticals Stock (ASX:PAR)Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Read More Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide PAR Stock News HeadlinesApril 19, 2024 | msn.comParadigm Signs ‘Fire Island’ & ‘How To Get Away With Murder’ Actor Conrad RicamoraApril 19, 2024 | msn.comParadigm makes key submission to US FDA to advance osteoarthritis Phase 3 trialApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 17, 2024 | msn.comSheboygan jazz masterclass at Paradigm will feature Milwaukee Jazz Institute's managing directorApril 9, 2024 | msn.comWWE Star Damian Priest Signs With Paradigm (EXCLUSIVE)April 9, 2024 | benzinga.comMonad Labs Raises $225 Million in Funding Round Led by ParadigmApril 9, 2024 | sg.style.yahoo.com10 best makan places in Paradigm Mall JBApril 4, 2024 | msn.comReggie Bush Signs With Paradigm Talent Agency In All Areas, Launches Production CompanyApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 2, 2024 | msn.comMerkle Achieves $1 Billion Valuation with Paradigm Leading Funding SurgeMarch 27, 2024 | msn.comParadigm Signs ‘Red, White & Royal Blue’ Breakout Taylor Zakhar PerezMarch 20, 2024 | msn.comLit Agents Alysia Thomas, Kelsey Roberts Exit ParadigmMarch 19, 2024 | uk.movies.yahoo.comParadigm Hires Verve Alums Bill Weinstein, Devon Schiff As Lit AgentsMarch 19, 2024 | msn.comBill Weinstein Joins Paradigm Talent Agency Following Verve ExitMarch 19, 2024 | msn.comBill Weinstein & Paradigm At The Altar? – The DishMarch 18, 2024 | msn.comOcugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the HorizonMarch 13, 2024 | finance.yahoo.comShift Paradigm acquires design and technology consultancy Principle StudiosMarch 11, 2024 | msn.comMonad Labs in talks to raise more than $200 million round led by Paradigm, valuing the Jump Crypto–linked startup at $3 billionFebruary 29, 2024 | tmcnet.comParadigm by Puloli™ Announces Customers in Eagle FordFebruary 27, 2024 | msn.comJaime King Signs With ParadigmFebruary 27, 2024 | msn.comWhat’s in store for 2024: Paradigm BiopharmaceuticalsFebruary 23, 2024 | tmcnet.comGlobal Disinfection Robots Market Report 2024: Analysis of Funding and Investments for Developing Disinfection RobotsFebruary 22, 2024 | yahoo.comParadigm Hires Kyle Jensen and Jamie Kaye-Phillips, Promotes Matthew Nutty, Taps Brian Neal for Napoli Management GroupFebruary 20, 2024 | msn.comASX stocks striving to inject youthfulness into an aging world populationFebruary 14, 2024 | bloomberg.comParadigm’s Famed ‘White-Hat’ Hacker Unites Peers Against Crypto AttacksFebruary 11, 2024 | finance.yahoo.comParadigm Biopharmaceuticals Limited (ASX:PAR) Is Expected To Breakeven In The Near FutureFebruary 8, 2024 | morningstar.comParadigm Biopharmaceuticals Ltd PARSee More Headlines Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PAR CUSIPN/A CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,031Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.42% Return on Assets-72.47% Debt Debt-to-Equity Ratio0.86 Current Ratio3.83 Quick Ratio5.93 Sales & Book Value Annual Sales$79,224.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares351,200,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Paul John Rennie BSc (Age 65)Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman Comp: $1.75MDr. Donna L. Skerrett M.D. (Age 67)MS, Chief Medical Officer and Executive Director Comp: $1.26MMs. Abby Macnish Niven B.Com.B.Sc., C.F.A., Interim Company Secretary & Interim CFODr. Ravi KrishnanChief Scientific OfficerMr. Simon WhiteDirector of Investor RelationsDr. Michael ImperialeGlobal Head of Drug Safety & MPSMs. Beverley HuttmannCommercial HeadMs. Michelle CoffeyGlobal Head of Regulatory AffairsDr. Mukesh AhujaGlobal Clinical Head of OAMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPaul RennieSold 349,500 sharesTotal: $136,305.00 ($0.39/share)Helen FisherBought 10,204 shares on 5/18/2023Total: $10,020.33 ($0.98/share)Paul RennieBought 73,851 shares on 5/12/2023Total: $75,992.68 ($1.03/share) PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO). This page (ASX:PAR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
